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Riga, Latvia
Abstract. Cleft lip and palate (CLP) is a common congenital anomaly
with a complex etiology which has not been elucidated yet. This study
investigated whether expression of osteopontin (OPN), osteoprotegerin
(OPG), and osteocalcin (OC), which are essential for the normal craniofacial
bone remodelling, is not regulated in children with CLP. Alveolar bone
tissue samples were obtained from patients with complete bilateral (CB)
CLP (n = 14) during corrective plastic surgery and unaffected control
subjects (n = 9). OPN, OPG, and OC expression was assessed by
immunohistochemistry, and data were analyzed with the Mann-Whitney test.
OPN expression was observed only sporadically in the alveolar bone of
3 patients, in contrast to the control group (z = − 2.962; P < 0.003). The
number of OPG-positive bone cells varied from occasional to moderate,
in contrast to the control group (z = − 2.247; P = 0.025). OC-positive
osteocytes were present in moderate to numerous numbers in both patients
and controls, with no significant difference between them (z = − 1.356;
P < 0.175). The prominent expression of OC characteristic for CBCLP
affected hard tissue indicates a high potential of bone mineralization. Few
OPG-positive osteocytes in the bone tissue implicate the disregulation of
osteoclast differentiation, maturation, and activity, but few OPN-containing
cells may prove the common disregulation of bone remodelling during cleft
morphopathogenesis.
Introduction
In humans, cleft lip and palate (CLP) is the fourth most common congenital malformation
affecting approximately 1 per 600 newborns in European populations and causing significant
medical, psychological, and social ramifications. CLP is characterized by the incomplete
formation of structures separating the nasal and oral cavities including the lip, alveolus, and
soft and hard palates, with the most severe clefts extending completely through both soft
tissue and bone. Cleft lip and palate treatment is a complex procedure that may include
multiple plastic surgical corrections, which may result in the formation of scar tissue
that adversely affects the growth and development of facial and oral cavity tissues [1].
It has been reported that CLP in humans results in abnormal function and growth of the
maxilla [2]. Following surgery, patients are left with acute wounds that will need to heal
to allow restoration of function. The wound healing involves regeneration, cellular activity
changes, and remodelling. Non-collagenous proteins play a major role in angiogenesis
and osteoclastic bone remodelling, two vital processes for normal bone healing [3].
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Bone is a highly dynamic tissue and an important site of continuous tissue remodelling
during development, homeostasis, tissue remodelling and repair. Bone remodelling is a
cyclic and continuous physiological process and depends on the tightly integrated activity
of two cell types, the osteoblasts, which form bone, and the osteoclasts, which resorb
bone. In addition, bone cells play an important role in bone homeostasis during wound
healing [4].
Osteopontin (OPN) is a highly phosphorylated sialoprotein that is a prominent component
of the mineralized extracellular matrix of bone. OPN is expressed by various human
cell types in a variety of tissues, including bone, dentin, cement, cartilage, kidney, brain,
vascular tissue, epithelial tissue [5]. In bone, OPN is produced by differentiated osteoblasts
and osteocytes, and also by osteoclasts. It appears to be an important component of the
communication between these cells and there is strong evidence for the involvement of OPN
in the formation, migration, and attachment of osteoclasts and for their resorptive activity [6].
Bone cells secrete OPN physiologically during the process of bone remodelling. There is
evidence suggesting that OPN acts as a pro-inflammatory cytokine and plays an important
role in regulating inflammation process [7]. It has been shown that the OPN is expressed
in selected tissues during embryonic development. Moreover, OPN may certainly play a
role in the collagen deposition that is crucial for normal morphogenesis of the secondary
palate [8].
Osteoprotegerin (OPG) is the main osteoclastogenesis modulator. It is a member of
tumour necrosis factor receptor superfamily also known as osteoclast inhibitor factor
produced by a variety of cells including osteoblasts, osteocytes, endothelial cells, vascular
smooth muscle cells, fibroblasts as well as hematopoietic and immune cells. The cytokine
OPG protects the skeleton by binding to RANKL and preventing it from interacting with
RANK. It prevents the proliferation and differentiation of osteoclasts that increases bone
density and volume [9]. The evidence showing the importance of OPG in bone biology was
provided by studies based on genetic experiments [10–12].
Osteocalcin (OC) or bone Gla-protein is the most abundant osteoblast-specific non-
collagenous protein. OC is predominantly synthesized by mature osteoblasts, osteocytes,
cementoblasts, odontoblasts and chondrocytes. It has an important role in both bone
resorption and mineralization. While OC is detected of high concentration in the bone
extracellular matrix, it also possesses several characteristic of a hormone [13].
To date, the physiological significance of non-collagenous proteins in CBCLP affected
alveolar bone is still unknown. This study investigated the expression of OPN, OPG, and OC
in complete bilateral (CB) CLP to identify possible changes in signalling pathways that could
lead to the aberrant maxillofacial bone remodelling observed in CLP.
Materials and methods
Study population
Samples were collected from the Cleft Lip and Palate Centre at the Institute of Stomatology of
Riga Stradins University from 14 patients with CBCLP and 9 unaffected control subjects. The
patient group comprised 9 males and 5 females. Samples of hard tissue were collected during
osteoplasty from children ranging in age from 6 years 4 months to 15 years and 4 months,
or upon tooth extraction from control subjects ranging in age from 6 years to 9 years. The
control group comprised 4 males and 5 females. This study was independently reviewed
and approved by the local Ethical Committee of the Riga Stradins University, and written
informed consent was obtained from all parents after the nature of the study had been fully
explained.
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Tissue sample preparation
For conventional light microscopy and immunohistochemistry, the tissue specimens were
fixed for 1 day in a mixture of 2% formaldehyde and 0.2% picric acid in 0.1 M phosphate
buffer (pH 7.2). They were then rinsed in thyroid buffer containing 10% saccharose for 12 h
and embedded in paraffin. Each block was cut into 4-µm sections that were mounted on
glass slides, deparaffinized, rehydrated through a graded alcohol series, and stained with
hematoxylin and eosin.
Immunohistochemistry
Tissue sections were labelled with the following primary antibodies: mouse anti-OPN at
1:100 (sc-73631; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), rabbit anti-OC
at 1:50 (sc-30044; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and goat anti-
OPG at 1:50 (sc-8468; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The signal
was visualized by biotin-streptavidin immunohistochemistry [14]. Images were captured
using a DC 300F camera (Leica, Wetzlar, Germany) and the image processing and analysis
software Image Pro Plus v.6.0 (Media Cybernetics, Silver Spring, MD, USA). The intensity
of immunostaining was graded semi-quantitatively on a scale of 0 to ++++, as follows:
0, no positive structures; 0/+, occasional positive structures; +, few immunoreactive
structures; ++, a moderate number of immunoreactive structures; +++, numerous
immunoreactive structures; and ++++, an abundance of immunoreactive structures in
the visual field [15]. The localization of staining was assessed at both tissue and cellular
levels.
Statistical analysis
Statistical analyses were performed using SPSS v.20.0 (IBM Corp., Armonk, NY, USA).
Results are expressed as mean ± SD. A Mann-Whitney test was used to compare groups and
a P value < 0.05 was considered statistically significant.
Results
OPN-positive structures were detected in 3 CBCLP cases, and the presence of OPN-positive
osteocytes was occasional (Fig. 1). OPN immunoreactivity was observed in osteoblasts and
osteocytes. In all control specimens, few OPN-positive cells were seen (Fig. 2). The total
number of OPN-positive the bone forming cells was significantly lower in the CBCLP than
in the control group (z = −2.962; P < 0.003) (Fig. 3).
OPG-positive structures were present in all hard tissue samples, and immunoreactivity
was detected in osteoblasts and osteocytes (Fig. 4). The number of OPG-positive bone
cells varied from occasional to moderate in all CBCLP cases. In controls, the number of
OPG-positive bone cells varied from few to numerous. There was significant difference
between the groups in the mean numbers of OPG-positive osteocytes (z = −2.247; P = 0.025)
(Fig. 5).
Of the 19 CBCLP specimens, all were positive for OC, although the signal was detected
in a moderate to numerous cells in both patients and controls, with no significant difference
between them (z = −1.356; P < 0.175) (Fig. 6). Moderate to numerous OC-positive
osteocytes were present in CBCLP specimens (Fig. 7), and there was no immunoreactivity
present in other structures of the alveolar bone.
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Figure 1. Occasional OPN-possitive osteocytes from the alveolar bone tissue of a 6-year-old child with
CBCLP. OPN IMH, X 200.
Figure 2. Abundant OPN-positive osteocytes in control group specimen. OPN IMH, X 100.
Discussion
Non-collagenous proteins play a key role in different physiological and pathological
conditions, including embryonic development, wound healing, inflammation, tumour growth,
calcification, and bone remodelling. The alveolar bone undergoes constant remodelling
process [16]. Various molecules contribute to the tissue regeneration associated with acute
bone wound healing, including OPN, OPG and OC molecules. Such molecules can be
identified to allow analysis of bone remodelling, and can be useful to determine the rate
or outcome of states of bone remodelling and therefore signal the success of surgical or
pharmaceutical interventions [17].
It was demonstrated that OPN has a role in cell adhesion, migration, cell survival and bone
remodelling [18–20]. Research in animal models has indicated that OPN deficiency alters
the functionality of multiple cell types, resulting in delayed early vascularization, altered
matrix organization and late bone remodelling [21]. Furthermore, OPN has been emphasized
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Figure 3. Comparison of OPN expression between study groups. Statistically significant differences
were observed.
Figure 4. Numerous OPG-possitive osteocytes in the hard tissue of a 8-year-old child with CBCLP.
OPG IMH, X 200.
Figure 5. Comparison of OPG expression between study groups. Statistically significant differences
were observed.
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Figure 6. Comparison of OC expression between study groups. No significant differences between
groups were observed.
Figure 7. Abundant OC-positive osteocytes from cleft region of a 6-year-old child. OC IMH, X 200.
as important for palate formation in recent study on foetal murine palates, which showed
significant changes in expression of OPN during craniofacial development [22]. Jakobsen
et al. by Gene chip analysis and staining with selected antibodies in human embryonic
palates found supportive evidence that OPN may play in the development of the normal
palate [23]. OPN-positive cell distribution varied from occasional to few positive structures
in the patients examined, and OPN expression in the alveolar bone was lower in the CBCLP
compared to the control group. These our results suggest an involvement of OPN in decreased
cell mobilization, protection, survival, resistance to apoptosis, and/or cell migration during
alveolar bone remodelling.
OPG is a powerful inhibitor of bone remodeling. It was previously demonstrated that
OPG knockout mice show severe osteoporosis, whereas overexpression of OPG causes
osteopetrosis [24]. Research in animal models has indicated that local delivery of OPG
inhibits bone modelling in tooth movement and during maxillary expansion [25, 26]. While
OPG is presumed to have a role in maxilla tissue remodelling, there has been no evidence
in support of this possibility in non-syndromic CBCLP affected hard tissue. The present
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study targeted the localization of OPG in the CLP affected alveolar bone. During the light
microscopic examination of immunohistological sections of the alveolar bone sections, there
were fewer OPG positive bone cells than unaffected individuals.
OC has been implicated in the mineralization of embryonic and adult bone [27], but
the changes in OC expression or function in CBCLP affected alveolar bone have not
yet been defined. Its absence leads to increase bone formation with bones of improved
functional quality without impairing bone resorption [28]. Furthermore, Cantatore et al.
(2005) have reported that osteocalcin stimulates angiogenesis and may play a role in bone
remodeling [29]. An immunohistochemistry study has suggested a role of OC during alveolar
bone healing process [30]. However, it is not known how the bone protein OC appear in
the CLP affected alveolar bone tissue. In the present study, OC expression was analogical
in CBCLP tissue compared to control tissue, providing evidence that extracellular matrix
mineralization is well regulated locally by OC in CBCLP patients.
Conclusions
The prominent expression of OC characteristic for CBCLP affected hard tissue indicates
a high potential of bone mineralization. Few OPG-positive osteocytes in the bone tissue
implicate the disregulation of osteoclast differentiation, maturation, and activity, but few
OPN-containing cells may prove the common disregulation of bone remodelling during cleft
morphopathogenesis.
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